POLICY AND REGULATIONGLP-1
The FDA is proposing new rules that would permanently prevent specialty pharmacies from making their own versions of popular GLP-1 drugs like semaglutide and tirzepatide. This move could eliminate cheaper compounded alternatives that many patients have been using when brand-name drugs are unavailable or too expensive.